← Eichor
Study identifier: NCT06566807 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Condition: Marginal Zone Lymphoma  ·  Sponsor: Huai'an First People's Hospital

PhasePhase 2
Planned participants51
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of Orelabrutinib combined with Obinutuzumab for previously untreated MZL.

This description comes directly from the study's public registry record.

Talk to the study team

Chunling Wang  ·  15189552696  ·  wcl6506@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital#Huai'an, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06566807